NASDAQ:RLAY

Relay Therapeutics Stock Insider Trading

etoro logo Buy RLAY
*Your capital is at risk
$15.30
-0.400 (-2.55%)
At Close: Jun 03, 2026

Relay Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -12.20. In total, the insiders bought 5.82M and sold 889.21K RLAY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-12.20
Buy 5.82M shares
Sell 889.21K shares
32% Buy Activity
Moderate Positive Correlation
Buy Signal Low Confidence
Jan 13, 2026

Analysis Breakdown:

  • Weakened by a contradictory negative Insider Power Score.
  • Partially supported by a positive historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
May 14, 2026
Sell
Common Stock
S-Sale
Catinazzo Thomas
Chief Financial Officer
C-Suite Officer 17 717
Value: $227.8K
Apr 28, 2026
Sell
Common Stock
S-Sale
Bergstrom Donald A
President, R&d
CEO / President 1 490
Value: $22.0K
Apr 28, 2026
Sell
Common Stock
S-Sale
Rahmer Peter
See Remarks
Officer 753
Value: $11.1K
Apr 28, 2026
Sell
Common Stock
S-Sale
Catinazzo Thomas
Chief Financial Officer
C-Suite Officer 972
Value: $14.4K
Apr 09, 2026
Buy
Common Stock
M-Exempt
Catinazzo Thomas
Chief Financial Officer
C-Suite Officer 1 800
Value: $9K
Apr 09, 2026
Sell
Common Stock
S-Sale
Catinazzo Thomas
Chief Financial Officer
C-Suite Officer 1 800
Value: $27.0K
Apr 09, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Catinazzo Thomas
Chief Financial Officer
C-Suite Officer 1 800
Value: $9K
Apr 07, 2026
Sell
Common Stock
S-Sale
Catinazzo Thomas
Chief Financial Officer
C-Suite Officer 17 717
Value: $230.5K
Mar 09, 2026
Sell
Common Stock
S-Sale
Catinazzo Thomas
Chief Financial Officer
C-Suite Officer 17 717
Value: $178.2K
Jan 28, 2026
Sell
Common Stock
S-Sale
Catinazzo Thomas
Chief Financial Officer
C-Suite Officer 1 695
Value: $14.3K
Jan 28, 2026
Sell
Common Stock
S-Sale
Bergstrom Donald A
President, R&d
CEO / President 2 686
Value: $22.7K
Jan 28, 2026
Sell
Common Stock
S-Sale
Rahmer Peter
See Remarks
Officer 1 354
Value: $11.4K
Jan 27, 2026
Sell
Common Stock
S-Sale
Bergstrom Donald A
President, R&d
CEO / President 18 895
Value: $144.0K
Jan 27, 2026
Sell
Common Stock
S-Sale
Rahmer Peter
See Remarks
Officer 11 684
Value: $89.0K
Jan 27, 2026
Sell
Common Stock
S-Sale
Catinazzo Thomas
Chief Financial Officer
C-Suite Officer 13 820
Value: $105.3K
Jan 13, 2026
Buy
Stock Option (Right to Buy)
A-Award
Bergstrom Donald A
President, R&d
CEO / President 575 000
Value: $4.57M
Jan 13, 2026
Buy
Stock Option (Right to Buy)
A-Award
Rahmer Peter
See Remarks
Officer 475 000
Value: $3.77M
Jan 13, 2026
Buy
Stock Option (Right to Buy)
A-Award
Patel Sanjiv
President And CEO
CEO / President 1 450 000
Value: $11.5M
Jan 13, 2026
Buy
Stock Option (Right to Buy)
A-Award
Catinazzo Thomas
Chief Financial Officer
C-Suite Officer 400 000
Value: $3.18M
Jan 06, 2026
Sell
Common Stock
S-Sale
Patel Sanjiv
President And CEO
CEO / President 43 168
Value: $337.6K
Dec 31, 2025
Buy
Common Stock
A-Award
Rahmer Peter
See Remarks
Officer 994
Value: $3K
Dec 31, 2025
Buy
Common Stock
A-Award
Patel Sanjiv
President And CEO
CEO / President 994
Value: $3K
Nov 04, 2025
Buy
Stock Option (Right to Buy)
A-Award
Coats Lonnel
Director
Director 207 931
Value: $1.43M
Nov 04, 2025
Buy
Stock Option (Right to Buy)
A-Award
Dable Habib J
Director
Director 207 931
Value: $1.43M
Nov 04, 2025
Buy
Common Stock
J-Other
Coats Lonnel
Insider
Other 0
Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT RELAY THERAPEUTICS INC.
Relay Therapeutics
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for pa...
GOLDEN STAR
Ticker Change Signal Date
RUN
$12.83
18.86% May 06
GLBE
$31.61
5.35% May 05
SAP
$172.39
10.69% May 05
W
WCLD
$27.34
27.18% Apr 29
ADBE
$243.57
7.61% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE